Semaglutide vs Dulaglutide: What the Research Compares

Semaglutide and dulaglutide are prescription medicines, each approved by regulators for use in adults with type 2 diabetes and each belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class. They are separate molecules rather than two names for the same substance, which is the first point of confusion the comparison usually raises. Both act at the same receptor target, both are given by the subcutaneous route in their long-acting weekly formulations, and both have been studied in large randomised cardiovascular outcome programmes. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question involving treatment, suitability or supervision.

Naming: two molecules, one receptor target

Semaglutide and dulaglutide are generic (international non-proprietary) names. Each appears under one or more brand names in different approved products, and semaglutide exists in both injectable and oral formulations, while dulaglutide has been developed as an injectable. A comprehensive pharmacokinetic review of approved GLP-1 receptor agonists and one dual GLP-1/GIP agonist described the structural strategies used to extend half-life across the class, including albumin-binding fatty acid acylation for semaglutide and fusion of a GLP-1 analogue sequence to an immunoglobulin Fc fragment for dulaglutide (PMID 40330819). Those different engineering choices explain why two medicines that engage the same receptor have different absorption and elimination profiles.

A state-of-the-art review of GLP-1 receptor agonists in type 2 diabetes placed both agents within the same therapeutic family and described the shared mechanism: receptor activation that enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying and acts on central pathways regulating appetite (PMID 33068776). The review also noted that agents within the class differ in structure, duration of action and the clinical endpoints their individual trial programmes were powered to measure (PMID 33068776).

Head-to-head evidence in the literature summarised here

The verified papers summarised on this page do not include a randomised trial that compared semaglutide directly against dulaglutide. What they do include are class-level syntheses that pooled separate trials of several GLP-1 receptor agonists, plus agent-specific analyses of semaglutide. Readers comparing the two should therefore treat the sections below as parallel evidence bases rather than as a contest with a declared result. A systematic review and meta-analysis of cardiovascular outcome trials pooled seven randomised trials of GLP-1 receptor agonists in type 2 diabetes, a set that included trials of semaglutide and dulaglutide among other agents (PMID 31422062). Pooled analyses of this kind describe the class average and are not designed to rank one member against another.

Side-by-side comparison

What studies measured for semaglutide

Semaglutide has an agent-specific cardiovascular literature. An analysis of findings from SUSTAIN 6 and PIONEER 6 examined cardiovascular safety and benefit with semaglutide in people with type 2 diabetes, covering the subcutaneous formulation in SUSTAIN 6 and the oral formulation in PIONEER 6 (PMID 33854484). The authors reported that both trials were designed around major adverse cardiovascular events as the primary composite endpoint and discussed how those results were interpreted alongside the wider class (PMID 33854484).

Oncology questions have also been examined specifically for this molecule. A systematic review and meta-analysis of semaglutide and cancer pooled randomised trial data and reported that overall malignancy risk was not significantly increased in the pooled trial populations, while noting the limits of trial duration for detecting long-latency outcomes (PMID 37531876). A separate 2025 JAMA Ophthalmology study investigated nonarteritic anterior ischemic optic neuropathy among people exposed to semaglutide, adding to an ophthalmic safety signal that researchers described as requiring further study (PMID 39976940).

What studies measured for dulaglutide

Dulaglutide appears in this citation set chiefly through class-level work rather than through molecule-specific reviews. The 2019 systematic review and meta-analysis of GLP-1 receptor agonist cardiovascular outcome trials reported that the class reduced major adverse cardiovascular events by roughly 12 percent and a composite kidney outcome by roughly 17 percent compared with placebo across the pooled trials, with the kidney signal driven largely by albuminuria (PMID 31422062). The same analysis reported that the pooled data did not show increases in severe hypoglycaemia, pancreatitis or pancreatic cancer (PMID 31422062). Because the analysis pooled agents, those estimates describe the class rather than dulaglutide in isolation.

The state-of-the-art review covering GLP-1 receptor agonists in type 2 diabetes similarly discussed glycaemic efficacy, weight effects and tolerability across approved agents including dulaglutide, and emphasised differences in receptor pharmacology and formulation between class members (PMID 33068776). Pharmacokinetic and drug-drug interaction characteristics for approved agents, including dulaglutide, were catalogued in a 2025 review that compared absorption, distribution and elimination profiles across the class (PMID 40330819).

Pharmacokinetics and interaction research

Comparisons between GLP-1 receptor agonists often turn on how long each molecule circulates and how it affects the absorption of other medicines. The 2025 pharmacokinetics and drug-drug interaction review examined approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist, and reported that delayed gastric emptying is a shared mechanistic consideration when evaluating co-administered oral drugs (PMID 40330819). Questions about specific interactions belong to a prescribing clinician and a pharmacist who can see a full medication list.

Adverse Events: What Studies Report

Gastrointestinal complaints are the most frequently discussed tolerability issue across the class, and the state-of-the-art review reported nausea, vomiting and diarrhoea as the characteristic adverse effects of GLP-1 receptor agonists in type 2 diabetes trials (PMID 33068776). The pooled cardiovascular outcome trial meta-analysis reported no increase in pancreatitis or pancreatic cancer across the trials it combined (PMID 31422062). For the related incretin agent tirzepatide, a separate systematic review and meta-analysis examined pancreatitis and gallbladder or biliary disease specifically in type 2 diabetes and obesity populations (PMID 37908750), and a drug review of tirzepatide in type 2 diabetes summarised its own efficacy and safety dataset (PMID 38388874); those findings sit alongside, rather than inside, the semaglutide and dulaglutide evidence.

Rarer signals have been catalogued through case literature. A review of rare cutaneous adverse reactions associated with GLP-1 agonists collected published reports of skin reactions across the class and noted that the overall number of cases was small (PMID 38795152). The ophthalmic literature described above examined nonarteritic anterior ischemic optic neuropathy in semaglutide-exposed patients (PMID 39976940). None of these publications resolves individual risk, which depends on medical history and is a matter for a treating physician.

Populations where data remain limited

Pregnancy is a clear example. A review of GLP-1 receptor agonist use in pregnancy reported that human data remain limited and that most available information comes from small observational series and animal studies, leading the authors to describe the evidence base as insufficient for firm conclusions (PMID 39181497). Questions about pregnancy, conception planning or lactation are for an obstetric clinician.

Research directions outside glucose control

Both agents sit within a class now studied for outcomes beyond glycaemia. A 2025 systematic review examined GLP-1 receptor agonists and alcohol use disorder, collecting preclinical and early clinical reports and concluding that evidence at that point was preliminary (PMID 41273789). A separate systematic review examined effects of GLP-1 analogues and agonists on the gut microbiota and reported heterogeneous findings across the included studies (PMID 40284168). These lines of work describe the class and do not establish comparative advantages between individual members.

How to read this comparison

1. Different molecules, shared target. The structural differences between the two agents were described in a class pharmacokinetic review (PMID 40330819).
2. Different evidence shapes. Semaglutide has molecule-specific analyses such as the SUSTAIN 6 and PIONEER 6 synthesis (PMID 33854484), while the cited dulaglutide evidence sits inside pooled class analyses (PMID 31422062).
3. Pooled estimates describe classes. The study that combined seven cardiovascular outcome trials reported an average effect across agents rather than a ranking (PMID 31422062).
4. Individual decisions are clinical. Formulation, comorbidity, interactions and monitoring are matters a prescribing clinician evaluates case by case.

Related reading

• Semaglutide overview
• Dulaglutide overview

References

• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (The Lancet Diabetes & Endocrinology, 2019)
• GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art (Molecular Metabolism, 2021)
• Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6 (Frontiers in Endocrinology, 2021)
• Semaglutide and cancer: A systematic review and meta-analysis (Diabetes & Metabolic Syndrome, 2023)
• Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy (JAMA Ophthalmology, 2025)
• A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist (Drug Design, Development and Therapy, 2025)
• Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis (Frontiers in Endocrinology, 2023)
• Tirzepatide: A Review in Type 2 Diabetes (Drugs, 2024)
• Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature (Archives of Dermatological Research, 2024)
• Glucagon-like peptide-1 receptor agonist use in pregnancy: a review (American Journal of Obstetrics and Gynecology, 2025)
• GLP-1 receptor agonists and alcohol use disorder: a systematic review (Alcohol and Alcoholism, 2025)
• Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review (Nutrients, 2025)